Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01752582
Other study ID # version1.1
Secondary ID
Status Completed
Phase N/A
First received December 7, 2012
Last updated March 10, 2016
Start date December 2012

Study information

Verified date March 2016
Source Sino Medical Sciences Technology Inc.
Contact n/a
Is FDA regulated No
Health authority China: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The objective of this study is a comparative evaluation of BuMA stent and of EXCEL stent in terms of the extent of neointima formation at 3 months after implantation using OCT.

This is a prospective, single center, randomized, open-label, non-inferiority study, which will enroll a total of 70 patients in Fuwai Hospital.All patients will be randomly assigned undergoing implantation of BuMA stent or EXCEL stent (in a 1:1 ratio). If non-inferiority was met, superiority test will be planned.


Description:

About 70 patients with clinical evidence of ischemic heart disease and / or a positive functional study and documented stable angina pectoris (Canadian cardiovascular society classification (CCS)1, 2, 3 or 4), or documented silent ischemia in de-novo, native, previously unstented vessel in Fuwai Hospital,will be randomly assigned undergoing implantation of BuMA stent or EXCEL stent (in a 1:1 ratio).

All of the patients will receive 6 months dual antiplatelet therapy and they will be followed (at the outpatient clinic) for up to 2 years. The follow-up visits will be conducted at 3 months (including angiographic/OCT investigation), 6 months, 1 and 2 years post percutaneous coronary intervention(PCI),in order to observe the Primary Endpoint and Secondary Endpoints.


Recruitment information / eligibility

Status Completed
Enrollment 80
Est. completion date
Est. primary completion date December 2014
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria:

- 18 to 85 years.

- Evidence of myocardial ischemia without raised troponin (e.g. stable or unstable angina, silent ischemia demonstrated by positive territorial functional study).

- The patient has a planned intervention of up to four de novo lesions, in different epicardial vessels.

- Lesion(s) must have a visually estimated diameter stenosis of =50% and <100%.

- Reference Vessel Diameter(RVD) must be between 2.5-4.0 mm

- Written informed consent.

- The patient and the patient's physician agree to the follow-up visits including angiographic follow-up and OCT controls at 3 months.

Exclusion Criteria:

- Evidence of ongoing acute myocardial infarction in ECG prior to procedure.

- Left ventricular ejection fraction(LVEF) <30%.

- Documented or suspected liver disease (including laboratory evidence of hepatitis).

- Known renal insufficiency (e.g. estimated glomerular filtration rate(eGFR) <60 ml/kg/m2 or serum creatinine level of >2.5 mg/dL, or subject on dialysis).

- History of bleeding diathesis or coagulopathy.

- The patient is a recipient of a heart transplant.

- Known hypersensitivity or contraindication to aspirin, both heparin and bivalirudin, antiplatelet medication specified for use in the study (clopidogrel and ticlopidine), sirolimus or stainless steel.

- Other medical illness (e.g. cancer, neurological deficiency) or known history of substance abuse (alcohol etc.) as per physician judgment that may cause non-compliance with the protocol or confound the data interpretation or is associated with a limited life expectancy.

- Pregnant or breastfeeding woman or woman in fertile period not taking adequate contraceptives

OCT exclusion criteria

- Severe tortuous, calcified or angulated coronary anatomy of the study vessel that in the opinion of the investigator would result in suboptimal imaging or excessive risk of complication from placement of an OCT catheter

- Total occlusion or thrombolysis in myocardial infarction(TIMI) flow 0, prior to wire crossing.

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label


Intervention

Device:
BuMA stent
About 35 patients will undergoing implantation of BuMA stent and receive 6 months dual antiplatelet therapy.
EXCEL stent
About 35 patients will undergoing implantation of EXCEL stent and receive 6 months dual antiplatelet therapy.

Locations

Country Name City State
China Fuwai Hospital, Chinese Academy of Medical Science BeiJing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Sino Medical Sciences Technology Inc.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary the percentage of the struts'neointimal coverage (%) at 3 months follow-up by OCT assessment. The primary outcome measure is the percentage of the struts'neointimal coverage (%) at 3 months follow-up by OCT assessment. three months after surgery No
Secondary Neointimal hyperplasia area/volume It will be measure the neointimal hyperplasia area/volume at 3 months follow-up by OCT assessment. three months after surgery No
Secondary Mean/Minimal Stent diameter/area/volume It will be measure the Mean/Minimal stent diameter/area/volume at 3 months follow-up by OCT assessment. three months after surgery No
Secondary Mean/Minimal Lumen diameter/area/volume It will be measure the Mean/Minimal Lumen diameter/area/volume at 3 months follow-up by OCT assessment. three months after surgery No
Secondary Mean/maximal thickness of the struts coverage It will be measure the Mean/maximal thickness of the struts coverage at 3 months follow-up by OCT assessment. three months after surgery No
Secondary Incomplete strut apposition It will be measure the incomplete strut apposition at 3 months follow-up by OCT assessment. three months after surgery No
Secondary Minimal Lumen Diameter(MLD) and Diameter stenosis percentage(%DS) post procedure and at 3 months three months after surgery Yes
Secondary Late Lumen Loss at 3 months three months after surgery Yes
Secondary Binary Restenosis (DS =50%) at 3 months All measurements will be made of the in-stent, in-segment, proximal and distal stent margins. three months after surgery Yes
Secondary Acute success rate It includes the device success,lesion success and procedural success. up to 7 days after surgery Yes
Secondary Device-oriented Composite Endpoints and its individual components at 3 months Device-oriented Composite Endpoint (DoCE) is defined as cardiac death, Myocardial Infarction(MI) not clearly attributable to a non-intervention vessel, and clinically-indicated target lesion revascularization. three months after surgery Yes
Secondary Device-oriented Composite Endpoints and its individual components at 6 months Device-oriented Composite Endpoint (DoCE) is defined as cardiac death, MI not clearly attributable to a non-intervention vessel, and clinically-indicated target lesion revascularization. six months after surgery Yes
Secondary Device-oriented Composite Endpoints and its individual components at 1 year Device-oriented Composite Endpoint (DoCE) is defined as cardiac death, MI not clearly attributable to a non-intervention vessel, and clinically-indicated target lesion revascularization. one year after surgery Yes
Secondary Device-oriented Composite Endpoints and its individual components at 2 years Device-oriented Composite Endpoint (DoCE) is defined as cardiac death, MI not clearly attributable to a non-intervention vessel, and clinically-indicated target lesion revascularization. 2 years after surgery Yes
Secondary Stent thrombosis according to the ARC definitions at 3 months three months after surgery Yes
Secondary Stent thrombosis according to the ARC definitions at 6 months six months after surgery Yes
Secondary Stent thrombosis according to the ARC definitions at 1 year one year after surgery Yes
Secondary Stent thrombosis according to the ARC definitions at 2 years 2 years after surgery Yes
See also
  Status Clinical Trial Phase
Recruiting NCT05196659 - Collaborative Quality Improvement (C-QIP) Study N/A
Completed NCT05088291 - Application of a New X-ray Protective Device in Coronary Interventional Therapy
Completed NCT03076801 - Does Choral Singing Help imprOve Stress in Patients With Ischemic HeaRt Disease? N/A
Completed NCT04584645 - A Digital Flu Intervention for People With Cardiovascular Conditions N/A
Not yet recruiting NCT04995159 - Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System N/A
Recruiting NCT02967718 - Innovation Research of Differentiation and Treatment Methods Based on CHD Phlegm and Blood Stasis Syndrome N/A
Completed NCT02888652 - Study on the Registration of Coronary Heart Disease Patients Undergoing PCI
Completed NCT02163044 - The Hellenic Postprandial Lipemia Study (HPLS)
Terminated NCT02045134 - Supplementation With Polyphenol-Rich Foods and Atrial Fibrillation After a Cardiac Surgery N/A
Active, not recruiting NCT02244853 - Heart Rate and Cardiovascular Diseases Prognosis in People With Stable Coronary Artery Disease N/A
Completed NCT02753829 - Home-based Cardiovascular Rehabilitation, Maintenance Phase, in Subjects With Coronary Artery Disease N/A
Terminated NCT01906957 - Cognition and Exercise Training N/A
Completed NCT02440893 - Understanding the Effect of Metformin on Corus CAD (or ASGES)
Completed NCT01826552 - Comparison of the Angiographic Result of the Orsiro Hybrid Stent With Resolute Integrity Stent Phase 4
Completed NCT01920009 - Impact of Motivational Interviews Within Pharmacy Care Upon Adherence to Cardiovascular Medicines N/A
Recruiting NCT01689688 - Healing Response to Everolimus-eluting Stent Implantation; Serial Assessment With opticaL Coherence Tomography N/A
Completed NCT01779401 - Clopidogrel Response Evaluation and AnTi-Platelet InterVEntion in High Thrombotic Risk PCI Patients N/A
Recruiting NCT01456364 - Intracoronary Stenting and Antithrombotic Regimen: ADjusting Antiplatelet Treatment in PatienTs Based on Platelet Function Testing Phase 4
Recruiting NCT01462799 - COR-PRIM: Problem-based Learning (PBL) After Coronary Heart Disease (CHD) - Long-term Evaluation in Primary Care of Self-care N/A
Completed NCT01486030 - Effect of Exercise Stress Testing on Peripheral Gene Expression Using Corus CAD (or ASGES) Diagnostic Test